BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) CEO Sells $374,475.40 in Stock

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) CEO John Oyler sold 1,460 shares of BeOne Medicines stock in a transaction that occurred on Tuesday, June 17th. The stock was sold at an average price of $256.49, for a total transaction of $374,475.40. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

John Oyler also recently made the following trade(s):

• On Monday, June 16th, John Oyler sold 3,680 shares of BeOne Medicines stock. The stock was sold at an average price of $266.05, for a total transaction of $979,064.00.
• On Friday, June 6th, John Oyler sold 5,127 shares of BeOne Medicines stock. The stock was sold at an average price of $252.77, for a total value of $1,295,951.79.

BeOne Medicines Trading Down 0.5%

ONC traded down $1.31 during trading on Wednesday, hitting $252.78. 230,441 shares of the company's stock traded hands, compared to its average volume of 447,828. BeOne Medicines Ltd. - Sponsored ADR has a 12-month low of $141.31 and a 12-month high of $287.88. The business's 50 day moving average is $243.44. The firm has a market cap of $27.69 billion, a PE ratio of -67.95 and a beta of 0.30. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.96 and a quick ratio of 1.71.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $1.22 earnings per share for the quarter, beating the consensus estimate of ($0.71) by $1.93. BeOne Medicines had a negative return on equity of 7.55% and a negative net margin of 9.40%. The firm had revenue of $1.12 billion for the quarter, compared to analysts' expectations of $1.12 billion. On average, equities analysts expect that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 EPS for the current year.

Wall Street Analysts Forecast Growth

ONC has been the topic of several recent analyst reports. Sanford C. Bernstein set a $259.00 target price on shares of BeOne Medicines in a report on Thursday, March 13th. JPMorgan Chase & Co. raised their price target on shares of BeOne Medicines from $311.00 to $317.00 and gave the company an "overweight" rating in a research report on Monday, April 21st. Macquarie increased their price objective on BeOne Medicines from $259.00 to $313.00 and gave the company an "outperform" rating in a report on Friday, February 28th. Royal Bank Of Canada dropped their price objective on BeOne Medicines from $312.00 to $311.00 and set an "outperform" rating for the company in a research note on Thursday, May 8th. Finally, JMP Securities set a $348.00 price objective on BeOne Medicines in a research note on Friday, February 28th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $319.00.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.